ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RCUS vs PGEN // RSI-14 & 200D SMA MOMENTUM

Arcus Biosciences Inc. (NYSE) VS. Precigen Inc. (NASDAQ) • 15-METRIC TALLY: RCUS 0 — PGEN 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PGEN
rsi-technicals
50.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCUS VS. PGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RCUS PGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -20.42% -3.78% -16.64 PGEN /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -35.30% 146.70% -182.00 PGEN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 PGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 30.0 50.3 -20.25 PGEN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.37B $2.38B -$7.7M PGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RCUS REV PGEN REV RCUS GROSS % PGEN GROSS % RCUS FCF PGEN FCF
FY 2025 $33.0M $9.7M — — -$484.0M -$89.8M
FY 2024 $51.0M $3.9M — — -$176.0M -$76.8M
FY 2023 $37.0M $6.2M — — -$306.0M -$66.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCUS // BETA —
PGEN // BETA —